Literature DB >> 1079693

Ocular manifestations of juvenile rheumatoid arthritis.

L T Chylack, D C Bienfang, A R Bellows, J S Stillman.   

Abstract

We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years. Thirty-six of the 210 patients (17.2%) developed iridocyclitis. Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis. However, 30% of the patients developed uveitis after 16 years of age. Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry. Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases. Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs. Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found. Typical keratoconjunctivitis sicca developed in three of the uveitis cases. This association with uveitis and JRA was not noted previously. Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1079693     DOI: 10.1016/0002-9394(75)90689-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

Review 1.  Emerging role of antioxidants in the protection of uveitis complications.

Authors:  U C S Yadav; N M Kalariya; K V Ramana
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Lensectomy for complicated cataract in juvenile chronic iridocyclitis.

Authors:  J J Kanski
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

3.  Cataracts in children with uveitis.

Authors:  I Casteels; D Taylor
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

4.  An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood.

Authors:  Clive Edelsten; Vickie Lee; Christopher R Bentley; Jack J Kanski; Elizabeth M Graham
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

5.  Screening for uveitis in juvenile chronic arthritis.

Authors:  J J Kanski
Journal:  Br J Ophthalmol       Date:  1989-03       Impact factor: 4.638

6.  Endogenous uveitis in children.

Authors:  J C Merritt
Journal:  J Natl Med Assoc       Date:  1979-07       Impact factor: 1.798

7.  HLA antigens and antinuclear antibody titres in juvenile chronic iridocyclitis.

Authors:  S Ohno; D H Char; S J Kimura; G R O'Connor
Journal:  Br J Ophthalmol       Date:  1977-01       Impact factor: 4.638

8.  Pars plana lensectomy in cases of cataract with juvenile chronic uveitis.

Authors:  H Verbraeken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-10       Impact factor: 3.117

9.  Inherited predisposition to iridocyclitis with juvenile rheumatoid arthritis: selectivity among HLA-DR5 haplotypes.

Authors:  M L Miller; P A Fraser; J M Jackson; M G Larson; R A Petersen; L T Chylack; D N Glass
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 10.  [Uveitis in conjunction with rheumatological diseases in childhood].

Authors:  C Sengler; R Keitzer; U Pleyer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.